Neuromuscular

Week-52 data from the phase 3 MINT trial show sustained improvements in MG-ADL and QMG scores with inebilizumab in patients with AChR-positive generalized myasthenia gravis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 17, 2026.

In honor of International Pompe Day, held April 15, 2026, NeurologyLive reviewed recent studies on the latest research and evolving standards of care for Pompe disease.

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Alexander Shustorovich, DO, an interventional pain medicine physician, discussed a unique case of sustained pain relief after spinal cord stimulation trial and its implications for neuromodulation strategies.

Here's some of what is coming soon to NeurologyLive® this week.

Diana Castro, MD, founder and director of the Neurology and Neuromuscular Care Center, discussed early phase 1b data on salanersen, an investigational therapy for patients living with spinal muscular atrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 10, 2026.

The director of neuromuscular medicine at Marcus Neuroscience Institute shared findings from an analysis presented at MDA 2026 that compared real-world infection rates associated with generalized myasthenia gravis therapies. [WATCH TIME: 8 minutes]

The director of Neuromuscular Medicine at Children’s Hospital of The King’s Daughters discussed the phase 4 RESPOND trial and how add-on nusinersen may improve motor function and biomarker outcomes in patients with spinal muscular atrophy following gene therapy.

The chief research officer of the Muscular Dystrophy Association spoke on the FDA's approval of a high-dose regimen of nusinersen and how it fits into an increasingly complex treatment landscape. [WATCH TIME: 11 minutes]

Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.

Following the FDA approval of tividenofusp alfa, this piece explores the evolving Hunter syndrome treatment landscape and highlights key pipeline therapies targeting both systemic and CNS disease burden.

Here's some of what is coming soon to NeurologyLive® this week.

A subpopulation analysis of the phase 2 ADHERE trial suggests clinical benefit and a favorable safety profile for efgartigimod PH20 in Chinese patients with chronic inflammatory demyelinating polyneuropathy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 3, 2026.

An international real-world analysis highlighted prolonged time to diagnosis and common misdiagnoses in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sarah Hoffmann, MD, PhD. [LISTEN TIME: 15 minutes]

Catch up on any of the neurology headlines you may have missed in March 2026, compiled into 1 place by the NeurologyLive® team.

Nazem Atassi, MD, SVP and Global Development Head of Neurology & Gene Therapy at Novartis, discussed 64-week STEER data and the evolving role of one-time gene therapy in SMA care.

The chief of neurology and director of Neuromuscular Medicine at Children’s Hospital of The King’s Daughters provided clinical insights on a number of SMA-related topics, including the recently approved high-dose nusinersen and the future of research and care.

Rachele Berria, MD, PhD, Medical Affairs at Chiesi Global Rare Diseases, discussed the clinical data and implications of newly approved every-4-week dosing of pegunigalsidase alfa for Fabry disease in Europe.

BridgeBio Pharma has submitted a new drug application to the FDA for BBP-418 for the treatment of limb-girdle muscular dystrophy type 2I/R9, supported by interim phase 3 trial data.

The FDA has approved a higher-dose regimen of nusinersen for spinal muscular atrophy, supported by DEVOTE data showing improved motor outcomes, reduced neurodegeneration markers, and a safety profile consistent with prior dosing.

Here's some of what is coming soon to NeurologyLive® this week.